Recent Updates
Recently added Catalysts
OVID Neutral Sentiment

Inchstone Project

Friday, September 29, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article provides an overview of Ovid Therapeutics, detailing its leadership, scientific strategy, and pipeline programs including OV329 and OV4071. It highlights the company's culture, values, and investor relations. However, it lacks specific news or developments regarding the Inchstone Project.
Price reaction · baseline $3.77 (2023-09-28 close) · hit pre-market · 5 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+1.9%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk

Full Press Release Details

• Our Company Our Story Leadership Board of Directors Scientific Advisory Board
• Our Science Our Pipeline Programs OV329 OV4071 & KCC2 Portfolio Program Posters and Publications Our Scientific Strategy Our Collaborations
• Our Patients
• Our Culture & Careers Our Culture Life at Ovid Our Values Open Positions
• Investors News Events & Presentations Stock Information Financials Governance Publications and Posters
• Contact Us
• Program Posters and Publications
• Our Story
• Leadership
• Board of Directors
• Scientific Advisory Board
• Our Pipeline
• Programs OV329 OV4071 & KCC2 Portfolio
• Program Posters and Publications
• Our Scientific Strategy
• Our Collaborations
• OV329
• OV4071 & KCC2 Portfolio
• Our Culture
• Life at Ovid
• Our Values
• Open Positions
• News
• Events & Presentations
• Stock Information
• Financials
• Governance
• Publications and Posters
ShareAdd on Google
Tags: OVID Viatris Investor Conferences Healthcare Ovid OV329 OV4071 biopharma pipeline
Last updated: Sep 29, 2023

Biotech snapshot

Cash runway
$166M liquidity · $5M/mo burn
~33 mo
Minimal dilution risk

Catalyst track record

+622%
best trade around OVID's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OVID.

See every catalyst's timing & PoA →